The proceeds will support the company’s activities with its ongoing clinical trial of i-FACTOR peptide enhanced bone graft for cervical spine applications. The financing will also help accelerate development of new products.
More Articles on Devices:
Orthopedic, Spine Device Companies Brace for 2.3% Tax Impact
Biovenus Opens Dutch Headquarters
Sens. Amy Klobuchar, Al Franken Seek to Delay Medical Device Tax
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.